Theravance Biopharma (TBPH) Accumulated Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Accumulated Expenses data on file, last reported at $8.7 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 62.09% year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a 62.09% increase from a year earlier, with the FY2025 full-year figure at $12.6 million, up 79.4% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $8.7 million, down from $12.6 million in the prior quarter.
• Over the last five years, Accumulated Expenses for TBPH reached as high as $12.6 million in Q4 2025 and fell as low as $4.5 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $7.3 million across 5 years, with a median of $7.0 million in 2022.
• On a YoY basis, Accumulated Expenses climbed as much as 727.77% in 2022 and fell as far as 52.46% in 2022.
• Year by year, Accumulated Expenses stood at $10.3 million in 2022, then sank by 37.53% to $6.4 million in 2023, then gained by 8.94% to $7.0 million in 2024, then soared by 79.4% to $12.6 million in 2025, then tumbled by 30.67% to $8.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.7 million in Q1 2026, $12.6 million in Q4 2025, and $10.3 million in Q3 2025.